NCT02185820View on ClinicalTrials.gov

Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

January 31, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

DRUG

Pomalidomide

DRUG

Dexamethasone

Trial Locations (1)

10126

Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino

All Listed Sponsors
collaborator

University of Turin, Italy

OTHER

lead

European Myeloma Network B.V.

NETWORK

NCT02185820 - Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) | Biotech Hunter | Biotech Hunter